Recommendations from the National Multiple Sclerosis Society Clinical Outcomes Assessment Task Force.
about
Influence of corpus callosum damage on cognition and physical disability in multiple sclerosis: a multimodal studyThe Multiple Sclerosis Functional Composite: a new clinical outcome measure for multiple sclerosis trialsFluoxetine for multiple sclerosisReduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosisPossible clinical outcome measures for clinical trials in patients with multiple sclerosisEvaluation of the six-minute walk in multiple sclerosis subjects and healthy controls.Cognitive impairments in multiple sclerosis: a review.Issues and practices in multiple sclerosis.Correlations between MRI and Information Processing Speed in MS: A Meta-Analysis.Vision and vision-related outcome measures in multiple sclerosis.Avonex Combination Trial in relapsing--remitting MS: rationale, design and baseline data.Outcome Measures in Clinical Trials for Multiple Sclerosis.Validity of low-contrast letter acuity as a visual performance outcome measure for multiple sclerosis.The Nine-Hole Peg Test as a manual dexterity performance measure for multiple sclerosisOutcome measures in relapsing-remitting multiple sclerosis: capturing disability and disease progression in clinical trials.Outcomes After Functional Electrical Stimulation Cycle Training in Individuals with Multiple Sclerosis Who Are NonambulatoryLongitudinal study of vision and retinal nerve fiber layer thickness in multiple sclerosis.Therapeutic developments in multiple sclerosis.Vision in multiple sclerosis: the story, structure-function correlations, and models for neuroprotection.In vivo evidence of glutamate toxicity in multiple sclerosis.The Multiple Sclerosis Performance Test (MSPT): an iPad-based disability assessment tool.Repeatability of the timed 25-foot walk test for individuals with multiple sclerosis.Randomized placebo-controlled phase II trial of autologous mesenchymal stem cells in multiple sclerosis.Health-related quality of life in partners of persons with MS: a longitudinal 10-year perspective.Quantitative measures detect sensory and motor impairments in multiple sclerosis.The multiple sclerosis visual pathway cohort: understanding neurodegeneration in MS.Relations of low contrast visual acuity, quality of life and multiple sclerosis functional composite: a cross-sectional analysisClinical trials in progressive multiple sclerosis: lessons learned and future perspectivesCorpus callosum microstructural changes correlate with cognitive dysfunction in early stages of relapsing-remitting multiple sclerosis: axial and radial diffusivities approach.Randomised, double blind, placebo controlled study of interferon beta-1a in relapsing-remitting multiple sclerosis analysed by area under disability/time curvesDisability outcome measures in therapeutic trials of relapsing-remitting multiple sclerosis: effects of heterogeneity of disease course in placebo cohorts.A comparison of health utility measures for the evaluation of multiple sclerosis treatmentsImmunosuppressants in advanced clinical development for organ transplantation and selected autoimmune diseases.Thalamic lesions in multiple sclerosis by 7T MRI: Clinical implications and relationship to cortical pathologyInterferon Beta-1a (AVONEX®) as a Treatment Option for Untreated Patients with Multiple Sclerosis (AXIOM): A Prospective, Observational StudySelecting Rehabilitation Outcome Measures for People with Multiple Sclerosis.Interferon-beta1a treatment for multiple sclerosis.Association of Cortical Lesion Burden on 7-T Magnetic Resonance Imaging With Cognition and Disability in Multiple SclerosisA population-based study of depressive symptoms in multiple sclerosis in Stockholm county: association with functioning and sense of coherence."Summary measure" statistic for assessing the outcome of treatment trials in relapsing-remitting multiple sclerosis
P2860
Q21560983-183D132C-4885-41BD-A86C-B13CCB706114Q22241715-CEEB991A-5BCD-4AA8-A1F0-EF8640A5479DQ24198247-3241174B-8167-481C-9209-D97EEADDFBF4Q24647406-7B3AE971-2C84-41F5-A211-740C97F924CAQ30433837-5ACDC51C-4846-489E-B077-A9B9FD4EF963Q30444767-1347173F-F977-4082-8612-F57425C263C1Q30671631-5FAFAE7C-7432-491B-8604-727F426C394FQ30751454-1E1B6989-CD03-44B9-812C-EF5FF8DB6020Q30814336-79F778E5-4BA7-462F-8CF2-4785B1121CCFQ30872452-AC1B9BE7-D568-4C9D-A037-B6123A6644BCQ31143314-F3A07F81-ACAF-4FB9-8FCB-5BF0F1F78AF8Q31160866-D806B57D-24DC-4A3C-B1A5-5BDE69B11CA3Q31162456-A69EC06B-43D1-42F8-8D97-5C258D2BA6CDQ33605465-635254BD-35BE-43CD-8674-6DFC5791857CQ33634866-6558AFA7-B7B8-49B0-B3D1-FA839FA5714EQ33769208-D54C8736-A9C2-44BB-B89F-6DF1C0C076FBQ33983613-3D7029F6-D15A-42D6-B508-8069AA618154Q34074776-217FDA4C-1DC2-4EAF-ADB2-12E61C35ABCFQ34076168-210AC439-32D6-42CD-84FD-1126F7C5B406Q34081836-79D23C56-AD2D-4AEA-9922-27C2E3AF2EBAQ34406601-AAD448E6-8B56-4290-A6A0-6C51DA5BF85EQ34593669-4EC1A7B1-C50C-46ED-8C24-06E86783D12EQ34600820-4625785A-ADA3-4D27-AC10-A2E05216DD34Q34768057-B6B4A955-35E9-4FC7-B24A-B6C85D272D2FQ34959472-56DF0C7E-C088-4BF4-8ADE-2A795D3371A1Q34991161-3621F160-D07A-453E-9587-F7861E98CA5CQ35098877-163DC003-DB44-49F8-B53F-0A2A2915523AQ35182733-C83CB2F6-FC80-482F-88F9-1E13F34C5EFAQ35391216-8E9C0D16-0212-44CB-99F0-2BE7279581C4Q35453326-923E7292-CA95-4DAB-AD2D-E83EED566B02Q35456042-E6E4E7A6-BE36-4A91-8B03-C28AA1DB698DQ35483470-34DFDD3E-BD99-4AA8-A921-D506BEA69B18Q35581131-D53CEE4C-D1BE-476C-8466-2F010AFDFAD1Q35843537-4DF3A6C6-7A31-452B-B209-B362670C45F9Q35902505-B0E952D8-5D26-4548-9EB4-E5AFB1927F82Q35974841-53C8F18F-479D-451E-9C5F-F68296A4DF6FQ36106748-CB3A6AE8-34B1-4491-942B-83B701ABC0F3Q36204696-CF6F8A83-69D0-454E-A2F0-FCC3A16D24F3Q36227300-01CA492B-683F-448A-B2E3-410870167ED0Q36318306-C628F66C-A6A6-4E61-9E00-C4738FB24F3C
P2860
Recommendations from the National Multiple Sclerosis Society Clinical Outcomes Assessment Task Force.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
1997年學術文章
@yue
1997年學術文章
@zh
1997年學術文章
@zh-hant
name
Recommendations from the Natio ...... utcomes Assessment Task Force.
@en
type
label
Recommendations from the Natio ...... utcomes Assessment Task Force.
@en
prefLabel
Recommendations from the Natio ...... utcomes Assessment Task Force.
@en
P2093
P2860
P356
P1433
P1476
Recommendations from the Natio ...... utcomes Assessment Task Force.
@en
P2093
Confavreux C
Reingold S
P2860
P304
P356
10.1002/ANA.410420318
P577
1997-09-01T00:00:00Z